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After the creation of an autogenous lower extremity bypass graft, the vein must undergo a series of dynamic structural
changes to stabilize the arterial hemodynamic forces. These changes, which are commonly referred to as remodeling,
include an inﬂammatory response, the development of a neointima, matrix turnover, and cellular proliferation and
apoptosis. The sum total of these processes results in dramatic alterations in the physical and biomechanical attributes of
the arterialized vein. The most clinically obvious and easily measured of these is lumen remodeling of the graft. However,
although somewhat less precise, wall thickness, matrix composition, and endothelial changes can be measured in vivo
within the healing vein graft. Recent translational work has demonstrated the clinical relevance of remodeling as it relates
to vein graft patency and the systemic factors inﬂuencing it. By correlating histologic and molecular changes in the vein,
insights into potential therapeutic strategies to prevent bypass failure and areas for future investigation are explored.
(J Vasc Surg 2015;61:203-16.)
Clinical Relevance: The autogenous vein bypass graft remains the gold standard revascularization method for the ischemic
limb. Newly implanted vein grafts undergo dramatic structural changes in response to the new high-ﬂow, high-pressure
environment. These changes, which are commonly referred to as remodeling, include a pronounced inﬂammatory
response accompanied by the development of a neointima and signiﬁcant changes in matrix composition. Similar to how
maturation of arm veins predicts the performance of an arteriovenous ﬁstula, recent translational work has demonstrated
that remodeling of the vein graft is important for subsequent patency of the lower extremity bypass graft.The autogenous vein bypass remains the most effective
and durable revascularization strategy for patients with
lower extremity ischemia despite the seemingly exponential
proliferation of endovascular devices and techniques. In the
United States, w250,000 coronary artery and 80,000
lower extremity vein grafts are implanted per year.1 Vein
grafts, in contrast to inanimate stents or prosthetic grafts,
are living and evolving conduits that respond to hemody-
namic stimuli and to signals from the local environment.2
Recent randomized controlled trials inform us that 30%
to 40% of coronary and lower extremity vein grafts occlude
or develop signiﬁcant stenosis within the ﬁrst year after
implantation.3,4 These ﬁgures have largely remained
unchanged for the past several decades.5 On one hand,
this is a cause for optimism because results remain constant
despite ever more challenging and complex patients.5 On
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Endophlebectomy of vein graft stenosis, described
ﬁrst in 1965 at the University of Rochester, was used to
treat a 56-year-old man whose femoropopliteal bypass
developed a 1-cm stenosis 16 months after its construc-
tion.6 Here, the authors described a white ﬁbrous tissue
that was sharply excised, and the graft was repaired with
a vein patch angioplasty. This all-too-familiar description
betrays the underlying inﬂammatory mayhem that cons-
pired to produce such a bland-appearing lesion. We now
characterize the lesion as intimal hyperplasia, which is
present to some extent in all vein grafts.
Unlike coronary bypass grafts, duplex surveillance of
lower extremity vein grafts can detect hemodynamically
signiﬁcant stenosis due to the vein graft’s superﬁcial loca-
tion within the leg. The distribution of ultrasound-
detected stenosis is diffuse in w12% vein grafts, but most
stenotic lesions are focal, often occurring in the perianasto-
motic regions or at valve sites.7-9
LIMITATIONS OF EXISTING ANIMAL MODELS
Growth factor inhibitors, transcription factors, cell
cycle regulators, immunomodulators, and nitric oxide
(NO) donors, among others, have all been effective at
reducing intimal hyperplasia in experimental models.10
Yet surprisingly, very few of these have entered into phase
1 human clinical trials. The lack of translation may be
because existing animal models do not adequately203
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structed with short interposition grafts in high-ﬂow envi-
ronments, produce minimal to moderate stenosis, and
rarely develop the severe occlusive lesions seen in the
human vein grafts. Most preclinical programs have rela-
tively short end points, commonly 28 days, which may
not be sufﬁcient to account for the late lumen loss due
to ﬁbrous expansion.11-14 The healing of human vein grafts
is known to occur well beyond this time frame, suggesting
more long-term models are necessary to fully study
complex mature lesions.
THE REMODELING OF HUMAN VEIN BYPASS
Although the extent and time frame of development of
intimal hyperplasia in animals substantially differs from
humans, one important similarity is the ability of the vein
to rapidly remodel to stabilize hemodynamic stress.12,15
The idea of human vein graft remodeling is hardly novel.
Szilagyi et al16 noted in the 1960s studying autopsy speci-
mens that vein grafts had increased their diameter by as
much as 50% to 75%. More recently, serial ultrasound
studies in patient cohorts have demonstrated in vivo
changes in human vein grafts.17
Remodeling of the vein graft can be thought of as the
morphologic and geometric changes in the vein that
happen through luminal dilation, reorganization of matrix
and collagen, and the development of a neointima. The
effects of the arterial environment on the vein have been
best characterized by Dobrin et al18,19 and others as four
pairs of deformations and counteracting stressesd
circumferential, longitudinal, radial (compressive), and
pulsatiledin addition to the well known shear stress.
Hence, exposing a vein graft to arterial pressure subjects
it simultaneously to deformations and stresses in nine
different directions.18,19
We hypothesized that the early geometric remodeling of
the vein graft is a crucial determinant to successful long-term
function of the bypass graft. To test this hypothesis, we initi-
ated a prospective cohort study to systematically determine
remodeling characteristics of lower extremity bypass grafts
during the ﬁrst year of implantation.20-23 High-resolution
ultrasound images were used to characterize luminal and
wall changes from a deﬁned region of the vein graft. We
also used pulse-wave velocity (PWV) analysis to determine
stiffness changes in the vein over time. PWV is the speed
at which the ﬂow pulse propagates through the conduit
and is one measure of stiffness that is relatively independent
of the outﬂow. Because it was impractical to map the entire
bypass graft, we used a 5-cm segment (no branches or
valves) of the graft as a surrogate for the behavior of the
entire graft. High-resolution M-mode ultrasound was
used to conduct vein graft lumenmeasurements at predeter-
mined times, beginning in the operating room after the
anastomoses were complete and then at 1, 3, 6, 9, and
12 months thereafter.
In these same patients, we collected demographic
information and cardiovascular risk factors and tracked
bypass-related and limb-related outcomes. Preoperativeblood samples were obtained to measure lipids, bio-
markers, and cytokines associated with inﬂammation and
thrombosis to assess their clinical value and also to provide
insights into mechanisms of vein graft failure. To ensure
that these markers were not spuriously elevated, any patient
with active infection, a recent procedure, or concurrent
systemic illness was excluded from biomarker evaluation.
Our early ﬁndings of this study were largely descriptive
in nature. We determined that most of the luminal and wall
remodeling of the graft occurs in the ﬁrst 30 days, followed
by relative stability. There was an increase of w25% in
lumen change of the vein graft between the operating
room and 1 month, but the luminal remodeling response
varied substantially.20,21 Although the lumens of most of
the grafts increased, about one-quarter decreased in size.
Similarly, wall thickness increased an average of 35% during
this same period. As expected from animal data, the initial
shear stress at the time of implantation was the single
biggest hemodynamic factor accounting for the variability
in luminal remodeling, but even so, only explained
w10% of luminal remodeling. This begins to get at some
of the discrepancy between animal and human data,
because most animal models of vein grafts use juvenile
healthy animals without severe systemic illness such as
advanced diabetes mellitus, hypertension, or dyslipidemia.
Our PWV studies determined that bypass grafts devel-
oped an increase in stiffness but were unexpectantly tempo-
rally delayed from the wall thickness changes. In fact,
stiffness initially decreased and then rapidly rose, reﬂecting
reorganization of matrix proteins.21 The arterialized vein
dramatically increased in stiffness by an average of w65%
from 3 to 6 months. Considering the vein wall consists
of three principle componentsdcells and proteoglycans,
elastin, and collagendonly an increase in the ﬁbrous
protein collagen could account for this.20 This observation
nicely complements animal data, whereby the wall thick-
ness changes during the ﬁrst 6 months were accompanied
by a marked increase in collagen production.11,12,24
These early observations began to paint a picture that
early luminal and wall thickness changes were followed
by a period of stiffening of the graft, and changes could
be measured for at least 6 months after implantation.
Because we encountered so much variability in lumen
caliber that was not explained by the graft’s inﬂow,
outﬂow, or hemodynamic stress, other explanations were
sought. By assessing the patient’s baseline level of inﬂam-
mation, determined by preoperative measurement of high
sensitivity C-reactive protein (hsCRP), an inverse correla-
tion was noted between inﬂammation and the magnitude
of luminal remodeling.22 Speciﬁcally, veins placed in
patients who had elevated preoperative hsCRP levels
($5 mg/L) dilated substantially less than those with
hsCRP <5 mg/L and were an average of 0.5-mm smaller
by the end of the ﬁrst month. This was true despite having
similar initial size at the time of implantation to those
patients with hsCRP <5 mg/L.
Other signiﬁcant demographic and clinical factors
found to be associated with the early remodeling of vein
Fig 1. A, Index segment diameter based on eventual loss of primary patency. Values shown represent the mean
diameter6 standard error of the mean at each interval. Although the starting diameter was at a similar size as those that
remained patent, vein grafts that eventually lost primary patency failed to dilate and had a signiﬁcantly smaller lumen
size over time. B, Early (30-day) remodeling is associated with primary patency (P ¼ .02). Adapted from Gasper et al.23
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the time of the operation, both of which have been shown
to be associated with vein graft patency.25,26 Speciﬁcally,
African American race was associated with less positive
remodeling during the ﬁrst month of implantation, and
vein grafts implanted in these patients never achieved the
diameter of those in Caucasians.23 Just as importantly, dia-
betes mellitus, hypertension, and hyperlipidemia were not
associated with remodeling, none of which have been
shown to be associated with reduced patency of lower
extremity vein grafts.
By linking bypass outcome data with serial imaging
data, we next determined that early vein graft remodeling
is associated with midterm vein graft patency independent
of initial vein size or other risk factors. Veins that do not
enlarge or get smaller during the ﬁrst postoperative month,
referred to by us as poor remodelers, have a 13-fold
increased risk of failure at 2 years compared with “robust
remodelers,” that is, those demonstrating >25% change
in lumen diameter (Fig 1).23 To put this in perspective,
the use of small veins for bypass only has about
a 2.5-fold increased risk of failure at 1 year,27 suggesting
that the remodeling of the vein in the ﬁrst 30 days is at least
as important as vein implantation size.
Thus, vein graft failure cannot be thought of as simply
a segmental hyperproliferative disease that develops within
a static tube. But rather, intimal hyperplasia develops
within a dynamic conduit, molded by hemodynamics
under the inﬂuence of systemic and regional factors.
Thus, inﬂammation,22 race,25 gender,28 and genetics29
can act globally on the entire vein graft to inﬂuence its
adaptation in the arterial circulation. However, should local
levels of shear stress and wall tension be impeded from
reaching or re-establishing baseline conditions due to local
environmental conditions, ﬂow disturbances, or intrinsic
vein disease, the proliferative intimal reaction would beexpected to continue and stenosis to supervene.30,31
Therefore one explanation for segmental stenosis may be
a hyperproliferative response superimposed on a restrictive
pattern of inadequate outward remodeling (Fig 2).
Given the critical importance of early vein graft remod-
eling, mechanistic insights may inform future local or
systemic therapy to improve patency. Studies speciﬁc to
lower extremity venous bypass remodeling are relatively
scarce, however. Examining other experimental models,
such as arteriogenesis (collaterogenesis), arteriovenous ﬁs-
tula (AVF) maturation, and even varicose vein develop-
ment, may provide important clues to direct future
research.32-34 There are, however, fundamental differences
between these models and vein bypass remodeling, as
denoted in Table I. We believe that revisiting some of
the early histologic and ultrastructural studies of experi-
mental vein grafts through the lens of recent molecular
biology is informative in understanding inciting pivotal
events.35-37
HISTOLOGIC REMODELING
The injury associated with venous harvesting and
implantation into the arterial environment is unlike any
other known vascular injury, including development of
atherosclerosis, balloon angioplasty and stenting, and
even creation of the AVF. It is abrupt, severe, and affects
the entire length of the bypass graft. The histologic and
ultrastructural consequences of this have been well
described and are depicted in Fig 3.35-41 Within 24 hours
to 3 days after pressurization, vein graft endothelial cells
(ECs) are focally absent or appear attenuated and elevated
by subendothelial edema and inﬁltrating inﬂammatory cells
that are present in the subendothelial space as early as
4 hours after implantation.42,43 Platelets, inﬂammatory cells,
and ﬁbrin are adherent to denuded areas of endothelium
where they release growth factors such as platelet-derived
Fig 2. Histologic evidence for negative remodeling and intimal hyperplasia as a cause of late lumen loss in a great
saphenous vein bypass graft. Masson Trichrome sections are from an 8-month-old femoral-posterior tibial artery vein
bypass graft that was explanted due to hemodynamically signiﬁcant stenosis identiﬁed by surveillance duplex ultrasound
imaging. The repair was constructed by an interposition graft, and an 8-cm piece of diseased segment was explanted,
registered, and serially sectioned from A (proximal graft) to H (distal graft). Note two areas of signiﬁcant stenosis,
sections A and B, and sections F-H with an intervening area of relatively normal vein. Although the vein was uniform in
size and in luminal caliber at the time of the original surgery, the stenotic areas demonstrate loss of total vessel area,
indicating lumen loss is due not only to intimal hyperplasia but also to negative remodeling. Note the amount of ﬁbrous
protein, as shown by the blue stain (arrows), in the stenotic segments of the graft.













Collateral vessels 30-50 mm 600-1000 2000% ??? <Arterial þ þ þ þ
Vein graft >3.0 mm 4.5-5.0 mm 20%-30% Medium (100-200 mL/min) Arterial þ/
AVF >3.0 mm 5-7 mm 100% High (600 mL/min) Low (tapers quickly) þ þ þ
AVF, Arteriovenous ﬁstula.
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endothelial growth factor, and insulin-like growth factor-1,
among many others.36,44,45 Areas of intact ECs subse-
quently slough or lose their barrier function so that they
are permeable to plasma proteins, macromolecules, lipids,
and growth factors. The remaining ECs demonstrate vacuo-
lation and increase in Golgi and rough endoplasmic retic-
ulum, indicative of conversion to a proinﬂammatory
phenotype.36 By 3 days, bare collagen, elastin, and other
matrix proteins are visible with adherent platelets, red blood
cells, and ﬁbrin.
Depending on the animal model, the endothelial
monolayer is largely restored by 10 days to 2 weeks, but
functional restoration in a 60-cm-long human bypass graft
likely takes far longer than it does in the short interpositiongrafts used in animals.36,39,46 Although the exact time
frame of human vein graft re-endothelialization is currently
not known, we do know that mature (>12 months) vein
grafts exhibit endothelium-dependent relaxation mediated
by NO.2 Evidence is emerging that the production of
endothelium-derived relaxing factors may be delayed for
up to 6 months after bypass graftingdlong after the critical
geometric remodeling period is completedsuggesting that
early luminal remodeling is independent of this process
(unpublished data from C.O., 2013). We now believe
that reconstitution of a physiologically functional endothe-
lium represents the third and ﬁnal clinical stage of vein graft
remodeling after luminal and wall thickness changes and
stiffening. Programs focusing on earlier restoration of
a functional EC monolayer and clinical measurements of
Fig 3. The histology of the healing autogenous vein graft. A, The intima in the normal vein is lined by large ﬂat
endothelial cells that are more permeable than those in arteries. The intima is separated from the media by fenestrated
internal elastic laminae. The tunica media is thin compared with an artery, with two or more layers of smooth muscle
cells (SMCs), whereas the adventitia is relatively thick, consisting of a loose collagenous network interspersed with
ﬁbroblasts, vasa vasorum, and small autonomic nerves. B, Within 24 hours after implantation, the vein grafts exhibit
signiﬁcant endothelial cell (EC) loss and subendothelial edema. Inﬂammatory cells, platelets, and ﬁbrin are seen
adherent to the surface and inﬁltrating underneath the attenuated endothelial cell monolayer. There is edema in the
tunica media, with extensive SMC necrosis or swelling and hypertrophy of the remaining SMCs, with inﬁltration of
inﬂammatory cells. C, By 2 weeks, there is re-endothelialization of the luminal surface and a developing neointima.
Although the endothelium is continuous, it remains dysfunctional, as evidenced by organelle hypertrophy and adhesion
molecule expression. The medial edema and inﬂammation is reduced, and there is increased collagen content. Surviving
medial SMCs appear hypertrophic, with increased rough endoplasmic reticulum and Golgi apparatus indicating
synthetic transformation. Over time, the adventitia becomes incorporated in surrounding tissue and vasa vasorum, and
adrenergic nerve ﬁbers grow in from adjacent arteries and connective tissue.D, By 4 weeks, there is a predominant layer
of intimal thickening characterized by SMCs embedded in a matrix of collagen and ground substance. Although early
medial thickening is caused predominantly by edema and inﬂammation, ﬁbrous transformation is responsible for late
medial thickening. Areas of the medial wall are devoid of cells and entirely replaced by ﬁbrosis. Clinically, stiffening of
the vein graft is likely from the increase in ﬁbrous protein as well as increased cross-linking of extracellular matrix
proteins.
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our understanding of vein graft failure with immediate
translational impact.47
Early after implantation, the media is marked by edema
and focal hemorrhage that likely account for the early thickness
changes, which can be measured by ultrasound imaging.36
The increased radial (compressive) stress of pressurization
and disruption from the vasa vasorum creates a zone of
ischemia in the vein media. Almost immediately, smooth
muscle cells (SMCs) show evidence of apoptosis or franknecrosis, as evidenced by marked vacuolated and pyknotic
nuclei.The remainingSMCs, like theECs, demonstrate severe
structural changes, including cellular hypertrophy, mitochon-
drial swelling, and bleb formation, alongwith increased rough
endoplasmic reticulum and Golgi. Inﬂammatory cells, partic-
ularlymacrophages, gradually increase in themedia and engulf
the necrotic SMCs, where asmany as 70% ofmedial SMCs are
lost during this early period.
Despite the substantial acute loss of medial SMCs,
most remaining SMCs resist apoptosis and enter the cell
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response transcription factors c-fos and c-jun of the acti-
vator protein 1 (AP-1) complex can be seen to be induced
in SMCs subjacent to the intima, where the ﬁrst-wave
growth and serum factors from adherent platelets and
inﬂammatory cells emerge.51,52 PDGF, insulin-like growth
factor-1, and other growth factors signal increases in SMC
migration and proliferation via phosphoinositol-3-kinase
(PI3K)-dependent pathways by binding to receptor tyro-
sine kinases and G protein-coupled receptors.53 PI3K, in
turn, activates numerous downstream pivotal effector
molecules related to cell proliferation, including mamma-
lian target of rapamycin (mTOR), p38 mitogen-activated
protein kinase, extracellular signal related kinases-1 and
-2, and Akt/protein kinase B, which collectively lead to
neointimal hyperplasia.54,55 Inhibition of c-jun and PI3K
reduced vein graft stenosis in experimental models.51,56
Many excellent reviews have addressed SMC proliferation
and migration with respect to vascular injury and intimal
hyperplasia.55,57-59
The adventitia is characterized by ﬁbroblasts within
a loose connective tissue stroma with occasional vasa vaso-
rum and vasa nervorum.39 Adventitial ﬁbroblasts, rich in
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases, have been shown to be a source of reactive
oxygen species (ROS) in blood vessels after mechanical
stretch and injury.60 In models of balloon injury and vein
grafts, perivascular ﬁbroblasts can be converted into myoﬁ-
broblasts, SMC-like cells that have migratory and synthetic
capacity.61-63 In vivo marker gene transfer studies show
that these cells can migrate into the developing intima
and contribute to intimal hyperplasia.63 Further evidence
is supported by disruption of transforming growth factor-
b or platelet-derived growth factor-BB signaling pathways
that can attenuate myoﬁbroblast migration into the neoin-
tima, reduce collagen content, and reduce constrictive
remodeling after balloon angioplasty.64,65
Soon after implantation, breaks in collagen ﬁbers, throm-
bosis of the vasa vasorum, and fragmentation of the adventitia
can be seen. The vasa vasorum, initially disrupted by harvest-
ing the vein, has been shown to return fully functional to the
adventitia and outer media as early as 7 days after implanta-
tion, where it participates not only in nourishing the healing
vein but also in inﬂammatory cell trafﬁcking into and out of
the vein graft.40,66 The newly implanted vein graft has been
generally assumed to receive oxygenation by passive diffusion
from luminal arterial blood.67 However, the vasa vasorum in
veins penetrates close to the intima and possibly through to
the lumen, so that retrograde ﬁlling by oxygenated blood
may be possible.68,69
The in situ bypass, originally described by Hall70 in
1962, and more recently advanced by Leather et al71 and
Shah et al,72 has several theoretic advantages over the
reversed saphenous vein graft: First, there is less dissection
and therefore less disruption of the vasa vasorum, which
should reduce the ischemia reperfusion injury. Second,
a small AVF could increase the shear stress through the
vein and improve outward remodeling. Third, there isa reduced size disparity at the femoral and distal anasto-
mosis. In practice, however, these theoretic advantages
have not translated to increased patency. It is likely that
traumatic lysis of the valve leaﬂets, mobilization of the
proximal and distal swing segments, and ligation of the
numerous AVFs offset these advantages.
The adventitia is also a compartment housing progen-
itor cells that contribute to vascular repair by differentiating
into a myoﬁbroblast phenotype and possibly other cell
types such as pericytes or ECs.73,74 Because the adventitia
lies between the vessel wall and surrounding tissues, it likely
contributes to vein graft remodeling by integrating diverse
signals from the vessel wall and the local environment.
Indeed, a number of experimental programs have exploited
adventitial delivery of therapeutic agents to the vein graft to
take advantage of these mechanisms.75-78
By 3 weeks, the media and adventitia demonstrate
extensive ﬁbrous replacement with collagen and a much
smaller amount of elastin. Histologic studies of mature
grafts demonstrate normally appearing endothelium, a thick
neointima composed of abundant collagen and ground
substance, and a relatively thinner media.41
MOLECULAR REMODELING
The cellular stress and tissue damage associated with
venous implantation activate the innate immune system
through several different mechanisms. Necrotic cellular
debris exposes modiﬁed lipids and proteins such as phos-
phoethanolamine and phosphorylcholine, which is recog-
nized by CRP, a member of the pentraxin family of
proteins. Pentraxins can be thought of as primitive anti-
bodies that circulate at normally low levels and police for
a limited repertoire of damage patterns commonly seen
in invading microbes or damaged cell surfaces.79 In this
sense, they can be thought of as the humoral arm of the
innate immune system.80 CRP can bind to these normally
cryptic epitopes, activate the complement system, and
recruit inﬂammatory cells to the injured vein, which exac-
erbates injury and necrosis. CRP may also activate local
SMCs to promote migration. Thus, although frequently
viewed as a nonspeciﬁc biomarker of inﬂammation,
CRP may act directly as a modulator of acute vascular
injury.81-86
The release of endogenous stress-response proteins,
such as heat shock protein 60, extracellular high mobility
group box 1, tenascin-C, and biglycan, are some of the ﬁrst
mediators of immune activation.87-91 These proteins,
collectively referred to as damage-associated molecular
patterns, are released by shear stress and matrix remodeling
and are the endogenous ligands of the Toll-like receptors
(TLRs).92 TLRs transmit stress signals through adaptor
proteins, such as myeloid differentiation protein-88, or
the Toll or interferon domain-containing adapter-inducing
interferon, to orchestrate the inﬂammatory response
through transcription factors, including nuclear factor-kB
(NF-kB).93,94 TLR-4 and its endogenous ligands are found
in human vein grafts, demonstrating its relevance to the
current discussion. In TLR-4-deﬁcient mice, vein grafts
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However, TLR-4-deﬁcient mice also exhibit reduced wall
thickening and reduced SMC content, causally implicating
this pathway in the formation of intimal hyperplasia and
making it difﬁcult to separate lumen dilation and wall
thickening.
To separate remodeling from intimal hyperplasia,
carotid ligation models have been used. After carotid artery
ligation, ﬂow in the contralateral carotid artery increases in
a compensatory manner, resulting in ﬂow-mediated vasodi-
lation without the induction of intimal hyperplasia. In mice
lacking TLR-4, there is defective ﬂow-induced outward
remodeling of the carotid artery and an increase in collagen
content, suggesting that TLR-4 is necessary for the matrix
turnover required for expansile remodeling.96 By contrast,
mice deﬁcient in the NF-kB p50 subunit demonstrate
increased ﬂow-induced outward remodeling and reduced
collagen content.97 Homodimers of p50 bind to DNA
but inhibit transcription activity by other NF-kB dimers,
thereby acting as a brake on NF-kB.98 Therefore,
p50-null mice have a more pronounced inﬂammatory reac-
tion in response to a ﬂow stimulus.97 Other studies show
that TLR-4 is integral to osteocalcin-induced myoﬁbro-
blast transformation from adventitial ﬁbroblasts, which
involves the inﬂammatory mediators, protein kinase C-d,
and cyclooxygenase 2.99 These studies highlight the link
between innate immune activation and matrix turnover
with respect to vascular remodeling.
ROS and nitrogen species are also integral messengers
in the innate immune system and important mediators of
hemodynamic remodeling in the vein. Shear stress in the
great saphenous vein, normally about 0 to 4 dynes/cm2,
abruptly rises to as high as 25 to 30 dynes/cm2 after
implantation,21 which is more than sufﬁcient for induction
of ROS.100 ROS can be generated from NADPH oxidases,
NO synthase isoforms, including inducible NO synthase,
xanthine oxidase, cyclooxygenase 2, cytochrome P450,
and the mitochondrial electron transport chain.101
Hydrogen peroxide generated from the electron transport
chain is essential for ﬂow-mediated dilation of the microcir-
culation and is a recognized hyperpolarizing factor.102
ROS, particularly peroxynitrite, generated from the
NADPH oxidase subunit p47phoxda cytosolic component
of the NADPH oxidase complexdin response to a high-
ﬂow ﬁstula, mediates matrix metalloproteinase (MMP)
gelatinase induction and outward remodeling of murine
AVFs.103 NADPH oxidase and superoxide are abundant
in the early vein graft wall because they are produced not
only by inﬁltrating neutrophils but also by SMCs and
ECs.104 In vein grafts and AVFs, increased superoxide
production has been directly correlated with dedifferenti-
ated cells in the neointima as well as with a reduction in
free radical scavenging enzymes, superoxide dismutase,
and Cu/Zn superoxide dismutase activity.105,106 The pres-
ence of peroxynitrite, a product of superoxide and NO,
suggests uncoupling of NO synthase isoforms and demon-
strates the altered redox state that exists in the healing
vein.103,106ROS are essential for activation of MMPs by cleaving
their prodomain and unmasking the active site.100,103,107
The MMPs consist of a family of w20 related proteins
that collectively can degrade all of the core proteins and
proteoglycans in the venous wall during remodeling.108
Because of this potential destructiveness, MMPs are tightly
regulated at several levels, including transcription, activa-
tion of protease proforms, secretion of stored MMPs, and
through binding to their natural inhibitor, tissue inhibitor
of MMP.109 Thrombin, plasmin, and neutrophil proteases
activate MMP-2 bound to membrane type 1 metalloprotei-
nase, whereas the signal transducer extracellular signal
related kinases-1 and -2 control MMPs in experimental
vein graft models.43,110 In addition, shear stress results in
phosphorylation of the p65 subunit of the inﬂammatory
transcription factor NF-kB, which along with AP-1 and
other transcription factors, stimulate MMP transcription
through coordinated promoter binding.100,109 MMP-2
and MMP-9, referred to as gelatinases due to their ability
to break down gelatin and several other collagens, in partic-
ular, the type IV collagen of the basement membrane,
are upregulated within as little as 3 hours after venous
implantation.43,111-113
Ultrastructural studies have documented progressive
loss of type IV collagen in the early bypass graft, indica-
ting destruction of the basement membrane (BM) that
normally surrounds 95% of saphenous vein medial
SMCs.114,115 The SMC BM not only represents a physical
barrier to SMC migration but also focal contacts between
SMC and BM laminin that keep the cell in a quiescent,
differentiated phenotype.116 Therefore, destruction of the
BM by MMPs liberates the SMC to migrate and also
results in loss of differentiation.117,118 Experimental inhibi-
tion of MMPs limits ﬂow-mediated arterial enlargement
and elastin degradation in rat and rabbit models,119,120
whereas various in vivo and ex vivo techniques to increase
tissue inhibitor of MMPs in the venous wall have been
successfully used to mitigate intimal hyperplasia.121-123
These studies highlight the fact that matrix turnover,
intimal hyperplasia, and vascular remodeling are inextri-
cably linked to one another.
The local renin-angiotensin-aldosterone system may
be an important link between vein graft collagen produc-
tion and inﬂammation. Aldosterone, signaling through
the mineralocorticoid receptor (MR), has been shown to
be an important mediator of vascular inﬂammation, oxida-
tive stress, and ﬁbrosis in clinical and experimental
settings.124-126 Aldosterone promotes vascular ﬁbrosis in
response to injury, and the MR regulates a number of pro-
ﬁbrotic genes in SMCs, including type 1 and type 3 colla-
gens and connective tissue growth factor.127 The MR has
been demonstrated to be upregulated in experimental
vein graft models as well as in human explanted vein grafts,
establishing its clinical relevance.128 More recently, antago-
nism of the MR with spironolactone reduced vein graft wall
thickening, ﬁbrosis, and inﬂammation in a mouse vein graft
model.126 In that study, spironolactone treatment reduced
the vein graft intima-media collagen area by 53% and
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(PMNs) by threefold.
The cytokine tumor necrosis factor-a (TNF-a) is also
involved in immune-mediated vascular remodeling in
animal models. In arteriogenesis, TNF-a colocalizes with
macrophages located in a perivascular cuff surrounding
remodeling arteries, and mice lacking TNF-a or the p55
TNF receptor show signiﬁcant reduction in collateral blood
ﬂow. By contrast, inhibitors of TNF-a attenuate collateral
artery development.129 Although ﬂow-mediated vascular
remodeling was once thought to be a phenomena intrinsic
to the vascular wall, recent work has demonstrated that
macrophages are prerequisite for dilation or shrinkage of
conduit vessels in response to ﬂow stimuli.130-132
INFLAMMATORY CELL PHENOTYPE AND THE
FATE OF REMODELING
The homing, trafﬁcking, and retention of inﬂammatory
cells into the vein graft wall is unlikely to be uniform along
the entire graft length but rather is dependent on local ﬂow
disturbances and injury variance.133,134 In general
however, monocytes and PMNs can bind to the vein graft
in high shear conditions (20-40 dynes/cm2) through the
leukocyte b2-integrins, aMb2 and aLb2 receptors, allowing
ﬁrm adhesion to vascular cells and >30 proteins of the
extracellular matrix (ECM), including ﬁbrinogen.135,136
Early induction of MMPs to breakdown BM and other
ECM barriers not only permits SMC migration out toward
the intima but also facilitates entry of PMNs and mono-
cytes into the vessel wall.43 Although macrophages are
essential for vessel remodeling, they also contribute to
the inﬂammatory state of the newly implanted vein, as evi-
denced in macrophage depletion studies in which there is
a reduction in inﬂammatory cytokines as well as intimal
hyperplasia.137,138
Monocyte chemotactic factor-1 (MCP-1) and its
receptor CC-chemokine receptor-2 is the classic chemoat-
tractant pathway for monocyte invasion in the vein graft.
Its importance in arteriogenesis is evidenced by the fact
that MCP-1 administration augments collateral artery
development after femoral artery ligation in experimen-
tal models.139 Conversely, transgenic mice deﬁcient in
MCP-1 have reduced collateral artery formation.140
MCP-1 has been shown to be induced in SMCs and ECs
with #24 hours of exposure to increases in circumferential
wall tension or stretch (cyclic stress) in a manner that
depends on the inﬂammatory transcription factor AP-1.141
AP-1 regulates the expression of many stress response
genes, including those associated with the proinﬂammatory
phenotype of ECs and vascular SMCs and is activated by
ROS.142 Increasing venous pressure in vivo increases
SMC proliferation and MMP-2 activation in an AP-1-
dependent manner.143 MCP-1 also directly participates in
growth and migration of SMCs by targeting cyclins
through the inﬂammatory transcription factor, nuclear
factor of activated T cells.144-147 Hence, cyclic stress may
induce MCP-1 production in vascular cells through AP-
1-dependent mechanisms, and in turn, MCP-1 can induceneointimal formation through nuclear factor of activated T
cells. Inhibition of MCP-1 or CC-chemokine receptor-2
reduces vein graft intimal hyperplasia.145,148
Other pathways are involved in inﬂammatory cell
recruitment to the vein graft besides MCP-1. The CXC
chemokine ligand-12, also called stromal cell-derived
factor-1a (SDF-1a), is an essential cytokine for stem cell
mobilization and is involved in homing circulating cells
to the vein graft. Theoretically, SDF-1a and its receptor,
CXCR4, could be beneﬁcial by recruiting progenitor cells
to repair the healing vein graft.149 However, CXCR4þ/
heterozygote mice have signiﬁcantly lower CXCR4 cell
surface receptor levels on bone marrow-derived mononu-
clear cells and are less responsive to SDF-1a. Vein bypasses
placed in these mice exhibit less inﬂammatory cell inﬁltrate
and less neointimal formation than those in wild-type
controls.150 A CXCR4 small molecule antagonist inhibits
neointimal formation and smooth muscle progenitor cell
mobilization after arterial injury in an apolipoprotein E/
mice model, providing further circumstantial evidence of
the importance of this pathway in vein graft failure.151
That inﬂammation and macrophages are involved in
inward and outward remodeling suggests that we should
not be looking solely at the magnitude of inﬂammation
but rather at the nature of the inﬂammatory response.131
Receptor characteristics and densities on the macrophage
cell surface dictate what it “sees” and contribute to prefer-
ential trafﬁcking and retention into blood vessels. For
example, longer-lived resident macrophages expressing
the chemokine receptor CXCR3 have been found in
humans within the adventitia of abdominal aortic aneu-
rysms and in areas of ﬂow disturbance, such as the carotid
bifurcation, suggesting that they are associated with patho-
logic states.130 CXCR3 is the receptor for interferon
(IFN)-induced protein of 10 kD, as well as monokine-
induced IFN-g. IFN-g, in turn, is the classic T-cell helper
(TH1) cytokine that induces macrophage activation and
production of the prototypical cytokines, TNF-a, inter-
leukin (IL)-1, and IL-6. These macrophages are further
classiﬁed by a low expression of the lymphocyte antigen
6c (Ly6clow) and CXCR3þ; Ly6clow macrophages are
known to patrol the microvasculature, including adventitia
microvessels.152 In mice, CXCR3 signaling contributes to
accumulation of adventitial macrophages and is also
involved in negative remodeling associated with reduced
ﬂow.130 Signaling through the CXCR3 receptor stimulates
the transglutaminase cross-linking enzyme, factor XIII
subunit a, which exerts its effects by cross-linking ECM
proteins and serves as a biologic glue.130,153,154 The
combination of ﬁxation of the ECM by cross-linking and
increased collagen production clearly would prohibit
luminal expansion. Might persistent ﬂow disturbance
around valve sites lead to a more pathologic inﬂammatory
cell subset accumulation into the wall, leading to focal
stenosis or failure of luminal expansion?
Polarization of the initial immune response may decide
the ultimate fate of the vein graft. Although inﬁltrating
monocytes contribute most conspicuously to vein graft
Table II. Three clinical stages of vein graft healing
Clinical stages Time frame Ultrastructural correlates Molecular correlates
Lumen dilation and increased
wall thickness
0-30 days Endothelial denudation, medial
wall edema
Inducers: DAMPs, neoantigens, ROS, serum
growth factors
Cellular homing/trafﬁcking Ampliﬁers: TNF-a, IL-1
Apoptosis/necrosis Receptors: TLRs, NLRs, IL-1R, and TNF-aR -1, -2
Proliferation Transducers: AP-1, NF-kB, NFAT
Matrix remodeling
Stiffness increase in Young’s
elastic modulus
3-6 months Myoﬁbroblast transformation Fibrosis (TGF-b, CTGF, SMAD1/2, TGFR1, TGFR2)
Collagen deposition Cross-linking ECM transglutaminases (factor XIIIa)
Endothelial recovery, vein graft
exhibits ﬂow mediated
vasodilation
>6 months Complete endothelial coverage,
barrier function, and return
of vasoreactivity
EDRF: eNOS, NO, prostacyclin, EDHF
AP-1, Activated protein-1; CTGF, connective tissue growth factor; DAMPs, damage associated molecular patterns; ECM, extracellular matrix; EDHF,
endothelium-derived hyperpolarizing factor; EDRF, endothelium-derived relaxing factors; eNOS, endothelium nitric oxide synthase; IL, interleukin; NFAT,
nuclear factor of activated T cells; NF-kb, nuclear factor-kb; NO, nitric oxide; NLR, nod-like receptor; ROS, reactive oxygen species; SMAD, mothers against
decapentaplegic homologue; TGF-b, transforming growth factor-b; TGFR, transforming growth factor-b receptor; TLR, Toll-like receptor; TNF, tumor
necrosis factor.
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phenotype switching might ultimately set the stage for
resolution or chronic inﬂammation and ﬁbrosis. The
professional antigen-presenting cell, the dendritic cell,
and CD3þ T lymphocytes have all been identiﬁed in
human vein graft specimens.155,156 Studies involving lung
and liver ﬁbrosis indicate that TH2-type dominant cytokine
responses involving IL-4, IL-5, IL-13, and IL-21 are pro-
ﬁbrotic, whereas TH1-associated cytokines, dominated by
IFN-g and IL-12, may be important in the resolution of
inﬂammation and possess antiﬁbrotic properties.157 IFN-
g and IL-12 treatment attenuates ﬁbrosis in experimental
pulmonary and renal models of ﬁbrosis.158-160
Of note, recent work has demonstrated that the re-
solution of inﬂammation, formerly viewed as a passive
decrescendo of proinﬂammatory signals, is in fact an
orchestrated process driven by speciﬁc “proresolving medi-
ators” (PRMs). Using unbiased lipidomics in models of
self-limited inﬂammation, researchers have discovered
that novel lipid mediators derived from polyunsaturated
fatty acids (PUFAs) are generated by speciﬁc biosynthetic
pathways.161-163 Four distinct classes of PRMs have been
recognized: the lipoxins, derived from the u-6 PUFA
arachidonic acid, and the resolvins, protectins, and mare-
sins, derived from the u-3 PUFAs eicosapentaenoic acid
and docosahexaenoic acid.164-166 Resolvins act via speciﬁc
G-protein-coupled receptors167-169 to reduce expression
of proinﬂammatory cytokines and adhesion molecules,
increase expression of anti-inﬂammatory cytokines, and
increase clearance of cellular debris.
Emerging evidence from our group and others has
demonstrated biologic activity of PRMs on vascular
cells.170,171 Lipoxins and resolvins regulate leukocyte-
endothelial interactions, reduce the formation of
ROS, and regulate the production of prostacyclin and
NO.172-176 More recently, we have demonstrated a broad
spectrum of beneﬁcial actions of D-series resolvins on
vascular cells.177 These include:1. Inhibition of leukocyte adhesion and adhesion mole-
cule expression;
2. Inhibition of cytokine expression;
3. Inhibition of vascular SMCproliferation andmigration;
4. Reduction in oxidative stress; and
5. A reduction in neointima formation after balloon
angioplasty in rabbit arteries.
These studies suggest that endogenous resolution
mechanisms may be an important element of the homeo-
static process of vascular remodeling and may offer a new
therapeutic target to manipulate vascular healing.
CONCLUSIONS
We have described three measurable, temporally
distinct clinical stages of vein graft remodeling: luminal
and wall thickness changes, changes in stiffness, and the
return of endothelial function (Table II). To gain some
mechanistic insights into these clinical stages, we have
attempted to relate them to histologic and molecular
changes associated with vein graft implantation. Of course,
this is an oversimpliﬁcation; for example, stimulating
macrophages alone through the TLR-4 and its two adaptor
proteins, as discussed, produces 775 unique proteins,
including 52 cytokines!178 Regulation of this single
receptor and its effectors not only occurs at the genetic
and epigenetic layers but also depends on adaptor protein
interplay, which can be synergic or redundant. As demon-
strated in Fig 2, intimal hyperplasia and constrictive remod-
eling often occur together to reduce lumen area,
suggesting common signaling pathways. However, we
have chosen to highlight speciﬁc examples to create
a temporal molecular framework of the innate immune
system’s role in the clinical stages vein graft remodeling.
Although inﬂammation is clearly crucial for remodel-
ing of the new vein graft, we must be speciﬁc when char-
acterizing inﬂammation. It is paradoxic that diabetes
mellitus and renal failure, two diseases hallmarked by
Fig 4. Hypothetic sequence of vein graft healing: Inﬂammation
peaks early after implantation and then subsides. The critical period
of vein graft luminal remodeling is largely complete by the ﬁrst
30 days. Functional endothelial cell (EC) recovery is temporally
delayed by several months. Mature vein grafts exhibit an endo-
thelial layer overlying a stable neointima. Endothelium-dependent
relaxation in mature grafts is mediated by nitric oxide (NO).
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shown to directly affect vein graft remodeling or
patency.179,180 It is possible that an intense tissue-level
inﬂammatory response to implantation that quickly
subsides is most conducive to vascular wall remodeling,
as denoted in Fig 4. However, should vein graft wall
inﬂammation fail to resolve, then the stage is set for path-
ologic remodeling, ﬁbrosis, and vein graft stenosis. Like-
wise, time and again, hemodynamic stress has been
shown in animal models to inﬂuence the development of
intimal hyperplasia.18,19,181 High shear conditions skew
the cytokine repertoire to a TH2-type response, with lower
inﬂammatory and higher anti-inﬂammatory cytokines
compared with low shear stress.182 However, blood ﬂow
and shear stress are largely unmodiﬁable factors dictated
by the inﬂow and outﬂow conditions and vein diameter.
Vascular surgeons know that vein grafts remain patent
and function successfully in conditions of extremely low
ﬂow, such as the pedal bypass.179 Even more extreme is
the bypass to an isolated popliteal artery segment, initially
described by Davis et al,183 which provides testimony to
the functionality of vein grafts whose outﬂow to the leg
is solely through popliteal artery collateral circulation.
Hemodynamic stresses are the blunt forces of global
remodeling, but it is the nature of the inﬂammatory
response that ﬁnely sculpts vein graft geometry.
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